A number of other research analysts have also commented on TRHC. TheStreet lowered Twin Disc from a b- rating to a c+ rating in a research note on Tuesday, June 11th. Guggenheim initiated coverage on Patterson Companies in a research note on Wednesday, April 17th. They issued a neutral rating and a $23.00 target price for the company. Cantor Fitzgerald initiated coverage on CytomX Therapeutics in a research note on Monday, May 13th. They issued an overweight rating and a $21.00 target price for the company. Piper Jaffray Companies upped their target price on Beigene to $180.00 and gave the company an overweight rating in a research note on Thursday, May 9th. Finally, Zacks Investment Research lowered GENEL ENERGY PL/ADR from a hold rating to a sell rating in a research note on Thursday, July 4th. Three analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $82.12.
Shares of NASDAQ TRHC opened at $54.95 on Friday. The company has a fifty day moving average price of $48.66. The company has a quick ratio of 1.73, a current ratio of 1.80 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of 161.62 and a beta of 1.63. Tabula Rasa HealthCare has a one year low of $40.86 and a one year high of $91.16.
In other Tabula Rasa HealthCare news, CEO Calvin H. Knowlton sold 8,270 shares of the stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $53.68, for a total transaction of $443,933.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, President Orsula V. Knowlton sold 8,000 shares of the stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $48.50, for a total value of $388,000.00. The disclosure for this sale can be found here. Insiders have sold 50,270 shares of company stock valued at $2,457,654 over the last quarter. Corporate insiders own 11.80% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in shares of Tabula Rasa HealthCare by 1.6% during the fourth quarter. BlackRock Inc. now owns 2,600,884 shares of the company’s stock worth $165,831,000 after purchasing an additional 40,174 shares during the last quarter. Polar Capital LLP bought a new stake in shares of Tabula Rasa HealthCare during the fourth quarter worth $3,953,000. Nicholas Company Inc. grew its holdings in shares of Tabula Rasa HealthCare by 6.5% during the fourth quarter. Nicholas Company Inc. now owns 77,485 shares of the company’s stock worth $4,940,000 after purchasing an additional 4,750 shares during the last quarter. Summit Creek Advisors LLC bought a new stake in shares of Tabula Rasa HealthCare during the first quarter worth $2,885,000. Finally, Advisor Group Inc. grew its holdings in shares of Tabula Rasa HealthCare by 547.9% during the fourth quarter. Advisor Group Inc. now owns 12,557 shares of the company’s stock worth $801,000 after purchasing an additional 10,619 shares during the last quarter. Hedge funds and other institutional investors own 85.92% of the company’s stock.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.
Featured Article: Different Types of Derivatives
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.